公开(公告)号：US10314910B2

公开(公告)日：2019-06-11

申请号：US15402888

申请日：2017-01-10

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/395 ,  A61K39/085 ,  C07K16/28 ,  A61K38/16 ,  C07K14/31 ,  C07K16/30 ,  A61K47/68 ,  A61K39/00

Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

公开(公告)号：US20220213194A1

公开(公告)日：2022-07-07

申请号：US17610897

申请日：2020-05-15

Applicant: NeoTX Therapeutics Ltd.

Inventor： Michal Shahar ,  Meir Azulay ,  Asher Nathan

IPC: C07K16/28 ,  C07K16/30 ,  A61K47/68 ,  A61P35/00

Abstract: The invention provides methods or compositions for treating cancer using a superantigen conjugate optionally in combination with a PD-1-based inhibitor.

公开(公告)号：US11607452B2

公开(公告)日：2023-03-21

申请号：US16710432

申请日：2019-12-11

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/085 ,  A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  A61K39/00 ,  A61K38/16 ,  C07K14/31 ,  C07K16/30

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

公开(公告)号：US20170258905A1

公开(公告)日：2017-09-14

申请号：US15402888

申请日：2017-01-10

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/395 ,  A61K38/16 ,  C07K16/28 ,  C07K14/31 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K38/164 ,  A61K39/085 ,  A61K39/39541 ,  A61K39/3955 ,  A61K47/6829 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/585 ,  A61K2039/6056 ,  A61K2039/86 ,  C07K14/31 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3053 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/40 ,  C07K2319/55 ,  C07K2319/74 ,  A61K2300/00

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

公开(公告)号：US20240100156A1

公开(公告)日：2024-03-28

申请号：US18166938

申请日：2023-02-09

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/395 ,  A61K38/16 ,  A61K39/00 ,  A61K39/085 ,  A61K47/68 ,  C07K14/31 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K38/164 ,  A61K39/0011 ,  A61K39/085 ,  A61K39/39541 ,  A61K39/3955 ,  A61K47/6829 ,  A61K47/6851 ,  C07K14/31 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3053 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/585 ,  A61K2039/6056 ,  A61K2039/86 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/40 ,  C07K2319/55 ,  C07K2319/74

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

公开(公告)号：US20230085724A1

公开(公告)日：2023-03-23

申请号：US17909212

申请日：2021-03-05

Applicant: NeoTX Therapeutics Ltd.

Inventor： Michal Shahar ,  Asher Nathan ,  Yael Sagi

IPC: A61K35/17 ,  A61K45/06 ,  A61P35/00

Abstract: The invention provides methods or compositions for treating cancer using an immune cell, e.g, a T-cell, e.g., a CAR T-cell, optionally in combination with a superantigen conjugate. The invention also provides methods for making immune cells, e.g, T-cells, e.g, CAR T-cells, for use in the treatment of cancer.

公开(公告)号：US20200078457A1

公开(公告)日：2020-03-12

申请号：US16411276

申请日：2019-05-14

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/395 ,  C07K16/30 ,  C07K14/31 ,  A61K38/16 ,  A61K47/68 ,  C07K16/28 ,  A61K39/085

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

公开(公告)号：US20240197784A1

公开(公告)日：2024-06-20

申请号：US18556473

申请日：2022-04-22

Applicant: NeoTX Therapeutics Ltd.

Inventor： Michal Shahar ,  Asher Nathan

IPC: A61K35/17 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464402 ,  A61K47/6829 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  A61K2039/507 ,  A61K2239/13 ,  A61K2239/47

Abstract: The disclosure provides methods and compositions for treating glioblastoma (GBM) using a 5T4-targeting agent, e.g., a superantigen conjugate comprising an anti-5T4 antibody.

公开(公告)号：US20230285588A1

公开(公告)日：2023-09-14

申请号：US18006243

申请日：2021-07-20

Applicant: NeoTX Therapeutics Ltd.

Inventor： Michal Shahar ,  Meir Azulay ,  Asher Nathan

IPC: A61K47/68 ,  A61P35/00 ,  A61K39/395 ,  A61K39/085 ,  A61K31/397

CPC classification number: A61K47/6851 ,  A61P35/00 ,  A61K39/3955 ,  A61K39/085 ,  A61K31/397 ,  A61K2039/6031

Abstract: The invention provides methods or compositions for treating cancer using a superantigen conjugate in combination with a B-cell depleting agent, e.g., an anti-CD20 antibody.

公开(公告)号：US11202829B2

公开(公告)日：2021-12-21

申请号：US16411276

申请日：2019-05-14

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/395 ,  A61K39/085 ,  C07K16/28 ,  A61K47/68 ,  A61K39/00 ,  A61K38/16 ,  C07K14/31 ,  C07K16/30

Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.